Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2008

View Archived Issues

Coffee, tea reduce cerebral infarction risk in male smokers

Caloric intake reduced with AC-2307 in obese subjects

ARISE trial data, mechanism of action study reported for AGI-1067

Benefits seen with metreleptin in patients with nonalcoholic steatohepatitis

Pfizer launches Toviaz once-daily treatment for the symptoms of overactive bladder

Gemin X closes series C financing to advance registration of obatoclax

FDA grants DuoCort orphan drug designation for adrenal insufficiency

FDA grants orphan drug designation for Marqibo in metastatic uveal melanoma

EMEA accepts for review UCB's MAA for Cimzia in rheumatoid arthritis

Repros initiates phase IIb comparative study of Androxal and Testim for male fertility

Halozyme reports positive results from phase I/IIa clinical trial of Chemophase

Genmab receives milestone payment from GSK for initiation of phase II study of ofatumumab

FDA accepts for review Acusphere's NDA for Imagify in coronary artery disease

Alpharma resubmits NDA for Embeda to FDA

PM-00104 shows preclinical activity against multiple myeloma via induction of p53

Roche reports results from pilot study of NT-proBNP in predicting CV-AE

GSK presents update on application to FDA for approval of cervical cancer vaccine Cervarix

FDA approves VGX's IND application for VGX-3100 DNA vaccine for cervical cancer

XTL completes patient randomization into phase IIb study of bicifadine

Epix resubmits Vasovist NDA to FDA

Ore files IND application with FDA for GL-1001 in inflammatory bowel disease

Preliminary response rate data reported for discontinued phase III trial of CoFactor

New agents for Alzheimer's disease and other neurological disorders reported in recent patents

Lev to submit Cinryze application to the EMEA for hereditary angioedema

New antiobesity agents claimed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...